LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Suletud

SektorTervishoid

7.1 1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.03

Max

7.1

Põhinäitajad
By Trading Economics
Sissetulek	7.8M 13M
Müük	-4M 159M
Kasumimarginaal	8.092
Töötajad	580
EBITDA	1.2M 30M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+171.79% upside

Turustatistika
By TradingEconomics
Turukapital	-95M 1.4B
Eelmine avamishind	6.1
Eelmine sulgemishind	7.1

Uudiste sentiment

By Acuity

41%

59%

129 / 374 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. nov 2025, 21:36 UTC

Tulu

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9. nov 2025, 21:22 UTC

Tulu

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10. nov 2025, 00:00 UTC

Market Talk

India Inflation Poised to Hit New Low -- Market Talk

9. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9. nov 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9. nov 2025, 21:05 UTC

Tulu

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9. nov 2025, 21:04 UTC

Tulu

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9. nov 2025, 21:03 UTC

Tulu

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9. nov 2025, 20:49 UTC

Tulu

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9. nov 2025, 20:49 UTC

Tulu

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9. nov 2025, 20:45 UTC

Tulu

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9. nov 2025, 20:45 UTC

Tulu

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9. nov 2025, 20:42 UTC

Tulu

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9. nov 2025, 20:42 UTC

Tulu

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9. nov 2025, 20:41 UTC

Tulu

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9. nov 2025, 20:41 UTC

Tulu

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9. nov 2025, 20:39 UTC

Tulu

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9. nov 2025, 20:39 UTC

Tulu

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9. nov 2025, 20:38 UTC

Tulu

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9. nov 2025, 20:38 UTC

Tulu

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9. nov 2025, 20:38 UTC

Tulu

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8. nov 2025, 13:10 UTC

Omandamised, ülevõtmised, äriostud

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8. nov 2025, 03:50 UTC

Omandamised, ülevõtmised, äriostud

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8. nov 2025, 03:41 UTC

Omandamised, ülevõtmised, äriostud

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8. nov 2025, 03:07 UTC

Omandamised, ülevõtmised, äriostud

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7. nov 2025, 22:36 UTC

Tulu

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7. nov 2025, 22:22 UTC

Tulu

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Rev $2.95B >CSU.T

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Net $210M >CSU.T

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q EPS $9.89 >CSU.T

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

171.79% tõus

12 kuu keskmine prognoos

Keskmine 19.27 USD 171.79%

Kõrge 30 USD

Madal 8 USD

Põhineb 11 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

129 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.